Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.
Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.
Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.
More melanomas are self-detected by women; men tend to have more melanomas in less visible locations.
A newly developed, evidence-based psychoeducational intervention effectively reduced fear of cancer recurrence and stress in patients at high risk for developing another melanoma.
Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.
Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro, research indicates.
Patients with localized melanoma see their supportive care needs peak at their initial cancer diagnosis and if they experience disease recurrence.
Response rates with PD-1 inhibitors in patients with acral and mucosal melanomas were similar to previously reported rates in patients with cutaneous melanoma.
Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.
Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.
New report doesn't change Task Force's prior statement on skin cancer screening issued in 2009
Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin SurgeriesJuly 21, 2016
Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.
The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer CareJuly 15, 2016
[Cancer Informatics] In this research, a microsimulation model framework is used to examine the impact of simultaneously altering curative treatment approaches in different phases of melanoma treatment.
Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.
De novo melanomas, which arise from clinically normal skin with no associated nevus, may be more aggressive than nevus-associated melanomas.
In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.
Population-based screening for melanoma performed by primary care providers does not cause substantial harm with respect to skin surgeries and dermatology visits.
PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.
Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic MelanomaJune 17, 2016
A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.
Cutaneous melanoma is rare on feet, but often advanced at point of diagnosis.
Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.
A newly discovered synthesized drug reduced the viability of melanoma cells without affecting normal cells in cell culture and mouse xenograft models of the disease. The drug, HA15, is a type of thiazole benzenesulfonamide.
Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.
Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
Combining radiation treatments with a new generation of immunotherapies is showing promise in the treatment of melanoma, according to a recent review.
Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.
- Beta-blockers May Improve Survival in Multiple Myeloma
- Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax
- Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC
- Adding Onartuzumab to Chemo Not Effective for HER2-, MET+ Gastroesophageal Adenocarcinoma
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Mental Health Disorder Linked to Poorer Survival in NSCLC
- Perindopril, Bisoprolol Not Effective for Preventing Trastuzumab-mediated Left Ventricular Remodeling
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|